Ampio (AMPE) Submits Pre-IND Package on Zertane to FDA
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) has submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OPKO Health (OPK) Submits Factor VIIa Phase 2a IND to U.S. FDA
- OM Group (OMG) Comments on FrontFour Capital's Intention to Nominate Directors
- Ashford Hospitality Trust (AHT) Prices 9.5M Common Follow-On at $10.65/Share
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!